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Multidrug-resistant tuberculosis has been a serious medical and epidemic problem all over the world.
Management of patients suffering from multidrug-resistant tuberculosis is complicated and therapy is
successful in 60–70% of cases only. Therapeutic strategies recommend the application of standardized or
an individual treatment regimen based on the results of susceptibility drug tests for second-line anti-
tuberculous drugs. The case study describes treatment for multidrug-resistant tuberculosis with indi-
vidual drug regimen adjusted according to the results of susceptibility tests. Although smear and culture
negativity was reached, course of disease was changed in the seventh year of the individual regimen, the
disease progressed and the patient died.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
New cases of tuberculosis (TB) in the world have increased
during the last several years. The number of persons is expected to
reach about 10 million in this time. TB is the leading cause of death
from a curable infectious disease and nearly 2 million patients die
yearly.1 Drug resistance has become a major problem in the treat-
ment of tuberculosis around the globe.2 For multidrug-resistant TB
(MDR TB) is characterised resistance at least to isoniazid and
rifampicin which are the main antituberculosis drugs. MDR TB has
been a serious problem among some countries of eastern Europe,
Asia and Africa. The best way to prevent the acquisition of resis-
tance is well-administered ﬁrst-line treatment for susceptible TB
cases. The Czech Republic with 10millions inhabitants is situated in
the centre of Europe. The incidence of TB is low. The number of
reported TB new cases and relapses has continuously declined over
the past years, from 1442 (14 per 100 000 population) in 2000 to
867 (9.8 per 100 000 population) in 2007. Incidence of MDR TB is
about 2% of all TB cases for several years. The risk factors for
resistance include previous treatment, inadequate chemotherapy,
not directly observed treatment, shortage of antituberculosis drugs,
and interruption of therapy. Drug resistance has developed very
often because of the inappropriately or poorly implemented
primary programs of tuberculosis control. These mistakes lead to
the acquired resistance.1 Resistance is caused by a genetic mutation.
Resistant mutants to any single antibiotic occur readily at random: þ420 241721093.
All rights reserved.in bacilli undergoing replication and may be selected for by not
using the adequate combination of drugs. Ongoing transmission of
established drug-resistant strains in a population is a signiﬁcant
source of new drug-resistant cases. Primary resistance occurs when
patient is initially infectedwith a resistant organism. The important
factor to stop transmission of MDR TB is quick identiﬁcation of
drug-resistant TB. Next step is early administration of adequate
treatment regimen designed for MDR TB. Management of MDR TB
is usually complicated and the main principles are arranged into
ﬁve components. The ﬁrst one is sustained political commitment
with necessary legislation, TB control programme and facilitation
to prevent emergence of more MDR TB cases. The second compo-
nent is a rational case ﬁnding strategy with correct and timely
diagnosis based on the quality assured culture and drug suscepti-
bility tests. The next point deals with appropriate treatment
strategies using second-line drugs in a standardized or an indi-
vidual regimen. The fourth important component is insurance of
uninterrupted supply of quality assured antituberculosis drugs.
Recording and reporting system with deﬁned patient categories
and treatment outcomes concludes the main management
principles.3
Treatment outcomes of MDR TB are successful in 60–70% of
cases only.4 Choice of optimal therapeutic strategy may be
controversial because there are few directly comparable published
protocols.5 However, several general guidelines for therapy were
already published.6 Generally, the selection of an optimal regimen
should be based on the analysis of the patient’s drug history and
the results of drug susceptibility tests for the ﬁrst- and second-
line drugs. Re-treatment regimens should always include two
drugs the patient has not taken before.7 Therapy is performed
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forms of TB or on the individual treatment regimens. The second-
line drugs are represented by aminoglycosides (capreomycin,
kanamycin, amikacin), thioamides (ethionamid, prothionamide),
ﬂuoroquinolones (oﬂoxacin, ciproﬂoxacin), cycloserine, clofazi-
mine, and para-aminosalicylic acid – PAS. The average daily
dosage of aminoglycosides is 15 mg/kg. For thioamides it is
10–20 mg/kg. Recommended daily dosage of ﬂuoroquinolones
is 7.5–15 mg/kg. Optimal dosage of cycloserine is 10–20 mg/kg,
clofazimine 100–200 mg and PAS 10–12 g. The second-line drugs
are characterised by the less effect and more adverse reactions. A
combination of 5–6 drugs offers the greatest chance of success.3
Duration of MDR TB therapy is much longer than the treatment of
the sensitive form of TB and should be last 18 months after the
ﬁrst negative culture. Surgery is considered for limited number of
patients with localised cavity and good lung function.82. Case study
Patient, a 43-year-old white-male smoker, presented himself
with elevated temperature and cough in year 1999. Epilepsy, liver
disease, chronic obstructive pulmonary disease (COPD) and no
evidence of drug use were mentioned in his anamnesis. A negative
result of HIV status was found on testing. A chest X-ray showed
inﬁltration on the left inferior lobe (Fig. 1). Patient was cured 6
months according to the category III as recommended by World
Health Organization (WHO) in Guidelines for national programmes
in second edition 1997 for new smear-negative pulmonary tuber-
culosis.9 Patient received directly observed therapy with a regimen
of isoniazid, rifampicin and pyrazinamid in the initial phase. For
continuation phase isoniazid and rifampicin were used for 4
months also under direct observation with good patient’s compli-
ance. The sputumwas smear and culture negative during the whole
treatment period.
New pathological ﬁndings in the right middle and lower zone
and left superior lobe were detected on regular control after 6
months of treatment on 2000. Sputum was culture positive for
Mycobacterium tuberculosis (M.TB) and therefore the regimen was
changed to unapplied drugs with the suspicion on resistant strain.Fig. 1. Posteroanterior chest radiograph with inﬁltration on the left inferior lobe at the
beginning of TB disease in 1999.Combination of streptomycin, ethambutol, ethionamid and taro-
ﬂoxacin was applied. Sputum sample was sent to the National
Reference Laboratory for drug sensitivity testing. The method of
minimal inhibitory concentration proved the presence of multi-
drug-resistant M.TB with resistance to rifampicin and isoniazid.
The regimen was adjusted to combination of amikacin, etham-
butol, oﬂoxacin, ethionamid and pyrazinamid. Amikacin was
applied for 3 months without any adverse events and without
elevation of creatinine values. The 3 months duration of daily
therapy of aminoglycoside was recommended by WHO from year
1997. The patient was in a good clinical status for the following 6
months. Bacteriological investigations of sputum were repeated
and positive culture ﬁndings were conﬁrmed during second and
third year of treatment without any signiﬁcant changes on the
chest X-ray. Because of the unfavourable bacteriological results,
susceptibility tests were repeated in 2002 and conﬁrmed resis-
tance to ethambutol.
Therapy was adjusted again and combination of oﬂoxacin,
ethionamid, pyrazinamid, and capreomycin was extended of
sensitive drug cycloserine to ensure the favourable course and
outcome of the therapy. The combination of all drugs was tolerated
very well. Patients suffered from COPD and he was placed on
bronchodilators. No interaction with antituberculous drugs was
observed. Capreomycin was applied for 3 months only and therapy
continued on regimenwith remaining four drugs. Although patient
was treated by combination of four sensitive drugs, the sputum
started to be smear and culture positive intermittently in
2003–2005. Drug susceptibility tests were again repeated in year
2004 with the same resistance result as in 2002. On the chest X-ray
bilateral inﬁltrations proved partial regression. The application of
the regimen continued during 2006 and patient remained in the
same clinical status. Sputum samples were examined weekly and
they started to be smear and culture negative. Despite that the
favourable bacteriological ﬁndings, the progression of inﬁltration
on the chest X-ray was detected in 2006. During next several
months the sputum samples and the clinical status of the patient
changed to worse. He was tired, grew slim, suffering from dyspnoe,
cough, sweating, and temperature. There were no signs of exacer-
bation of COPD, malignant disease or other underlying disease. The
evidence of prolonged inﬂammation and progression of malnutri-
tion increased and the chest X-ray proved bilateral worsening of
inﬁltrates and cavities due to MDR TB (Fig. 2). Patient died due to
the cardio respiratory failure after seven years of uninterrupted
individualized treatment given under direct observation.
3. Discussion
The antimicrobial resistance is the threat for global public health
that demands the international attention.10 Themain approaches to
the identiﬁcation of MRD-TB are the establishment of history of
previous TB treatment and drug susceptibility tests.6,11 Suscepti-
bility tests for the ﬁrst- and second-line drugs should always be
performed for patients with possible treatment failure or relapse.
This recommendation was followed also in this study case and
susceptibility test conﬁrmed multidrug resistance.
The monitoring of treatment efﬁciency is based on three indi-
cators: 1. clinical response, 2. chest radiographs and 3. repeated
sputum microscopy, culture and susceptibility testing.5 Patient
should be evaluated for symptoms and signs of tuberculosis,
adherence to treatment and adverse reactions to themedications at
least every month, sputum specimens for Mycobacterium tubercu-
losis smear and culture should also be obtained monthly. If cultures
remain positive after 2–4 months of treatment, susceptibility tests
should be repeated as it was done in this case. To ﬁnish the therapy
successfully, the regimen should always continue for 18–24months
Fig. 2. Posteroanterior chest radiograph obtained two weeks before patient’s death
shows bilateral extensive inﬁltrations with cavities due to MDR TB in 2006.
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however, was not the case of the patient studied as the tests turned
positive and the clinical status worsens.
Management ofMDR TB is quite complicated. General guidelines
were presented by Iseman and WHO including ﬁve essential
components for every national TB control programme with detec-
tion and treatment of drug-resistant TB.3,6 MDR TB is conﬁrmed in
patient whose infecting isolates are resistant in vitro to at least
isoniazid and rifampicin. Treatment regimen is based on estab-
lishment of standardized or suitable individualized drug treatment.
The individualized treatment regimen is based on the results of drug
susceptibility tests of the speciﬁc strain, patient’s treatment history
and changes of the infecting strain during the treatment period. The
therapy should be started in the hospital to permit observation of
intolerance and to allow a change of a regimen. The recommended
number of not previously used drugs for individual regimens varies
in the literature. Three or four drugs are usually recommended.6,12
The use of the second-line antituberculous drugs, which are more
expensive, more toxic and less effective than the ﬁrst-line drug, is
required.3,11 The therapy is adjusted and switched according to the
laboratory results of resistance pattern, clinical deterioration and
bacteriological ﬁndings of sputum samples.
Drug resistance is strongly associated with previous treatment
and can develop in some cases in less than 1 month.5 The proba-
bility of development of resistance to a drug increases with the
length of time in has been administered. Evidence of bacteriological
treatment failure during a period of regular drug administration is
highly suggestive of drug resistance. In this patient the conversion
from drug susceptible tuberculosis case to an MDR TB case is
supposed. Second-line antibiotics have lower bactericidal activities
compared with ﬁrst-line ones and therefore the selection due to
a reduced antibiotic pressure is faster. It could explain the changes
of susceptibility patterns, increasing drug resistance and the ﬁnal
unfavourable outcome seen in this patient.
Generally, the results of medical therapy of MDR TB are not
satisfactory and about 30% of treatment failure patients have poor
prognosis. Favourable bacteriological response to chemotherapy
usually occurs within 4 months.13 In this case study the bacterio-
logical conversion of sputumwas found much later. The case studydid not fulﬁl the criteria for surgery approach because of the
bilateral pulmonary ﬁndings and poor lung function tests’ param-
eters. The surgery was not used in his therapy. Duration of the
treatment of MDR TB up to 3 years is quite difﬁcult due to side-
effects and often not very successful.4 However, if the surgery is
contraindicated, the drug treatment remains the only possibilities
for the patient even the duration of therapy has been longer than
3 years. In this case was quite difﬁcult to ﬁnish the therapy after
3 years because the patient was in good clinical condition and there
was a hope for favourable outcome.
This study presents extremely prolonged course of MDR TB
with 7 years period of directly observed individual treatment
regimen. This regimen included use of several drugs that were
changed according to the susceptibility tests during the therapy
period. Drug susceptibility test was repeated with the aim to
conﬁrm the bacteriological resistance. The resistance pattern for
isoniazid and rifampicin was once changed and extended of
ethambutol. Its repeated version remained unchanged although
bacteriological ﬁndings were permanent smear and culture
positive. Despite that the transient improvement of the bacteri-
ological samples was documented after six years of the therapy,
the progression of the chest X-ray, smear and culture positive
ﬁndings and the worsening of the clinical status were observed
during the following months. There was found no other serious
or malignant disease contributing to the progression of clinical,
laboratory and radiological ﬁndings. The study documents that
even seven years long uninterrupted individual treatment based
on repeated susceptibility tests did not prevent patient from the
exitus letalis.
Rapid identiﬁcation of patients with MDR TB and effective
treatment reduces costs and prevents the spread of infection.14
MDR TB patients respond to treatment slowly and remain
sputum smear and culture positive longer than other TB patients
and they may infect more contacts. Therefore case ﬁnding
strategy based on national TB programme with quality assured
culture and drug susceptibility test is an excellent method of
distinguishing MDR TB cases from others. These patients can be
properly isolated and adequately treated.3 MDR TB is associated
with higher rates of failure and death than susceptible TB and is
more difﬁcult and expensive to treat. Health care systems should
adopt and expand programs of TB control including in addition
directly observed treatment, short course strategy of WHO, use of
second-line drugs for therapy of MDR TB and reducing of further
transmission.2
Conﬂict of interest statement
None of the authors have a conﬂict of interest to declare in relation
to this work.
References
1. Murray JF. Tuberculosis and HIV infection: a global perspective. Respiration
1998;65:335–42.
2. Espinal MA, Laszlo A, Simonsen E, et al. Global trends in resistance to antitu-
berculosis drugs. N Engl J Med 2001;344:1294–303.
3. Guidelines for the programmatic management of drug-resistant tuberculosis.
World Health Organization; 2006 (WHO/HTM/TB/2006.361).
4. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy
for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med
2003;348:119–27.
5. Caminero JA. Management of multidrug-resistant tuberculosis and patients in
retreatment. Eur Respir J 2005;25:928–36.
6. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med
1993;329:784–91.
7. Schachter EN. Tuberculosis: a global problem at our doorstep. Chest
2004;126:1724–5.
8. Bartu V. Multidrug-resistant tuberculosis in the Czech Republic: strategy and
therapeutic outcomes. Eur J Clin Microbiol Infect Dis 2007;26:603–5.
V. Bartu, E. Kopecka / Respiratory Medicine CME 2 (2009) 185–1881889. Treatment of tuberculosis: guidelines for national programmes. 2nd ed. Geneva,
Switzerland: World Health Organization; 1997 (WHO/HTM/TB97.220).
p. 25–31.
10. Shin-ich T, Hajime M, Masanobu H, Norioshi S, Ryoji M. Current surgical
intervention for pulmonary tuberculosis. Ann Thorac Surg 2005;79:959–63.
11. Sharma SK, Mohan A. Multidrug-resistant tuberculosis. A menace that
threatens to destabilize tuberculosis control. Chest 2006;130:261–72.12. Fujiwara PI, Simone PM, Munsiff SS. Treatment of tuberculosis. In: Reichman LB,
Hershield ES, editors. Tuberculosis. A comprehensive international approach. New
York: Marcel Dekker; 2000. p. 401–46.
13. Loddenkemper R, Sagebiel D, Brendel A. Strategies against multidrug-resistant
tuberculosis. Eur Respir J 2002;20(Suppl. 36):66–77.
14. Mohapatra PR. Fluoroquinolones in multidrug-resistant tuberculosis. Am J
Respir Crit Care Med 2004;169:920–1.
